https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50456 2 cm (4.5%) or grade 3 tumors (5.5%). These sustained reductions of the risk of recurrence with adjuvant exemestane + OFS, compared with tamoxifen + OFS, provide guidance for selecting patients for whom exemestane should be preferred over tamoxifen in the setting of OFS.]]> Wed 28 Feb 2024 15:10:42 AEDT ]]> Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50457 Wed 28 Feb 2024 15:09:41 AEDT ]]> Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer: TEXT and SOFT Trials https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22946 Wed 11 Apr 2018 16:42:13 AEST ]]> Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14183 Wed 11 Apr 2018 13:18:25 AEST ]]> Impact of CYO19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28241 Wed 11 Apr 2018 10:43:55 AEST ]]> Tailoring adjuvant endocrine therapy for premenopausal breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32778 Wed 07 Feb 2024 16:54:46 AEDT ]]> Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25887 Thu 21 Jul 2022 15:37:04 AEST ]]> Adjuvant ovarian suppression in premenopausal breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16697 Sat 24 Mar 2018 08:06:52 AEDT ]]> Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21497 Sat 24 Mar 2018 08:03:39 AEDT ]]> Treatment-induced symptoms, depression and age as predictors of sexual problem in premenopausal women with early breast cancer receiving adjuvant endocrine therapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41881 Mon 15 Aug 2022 14:09:04 AEST ]]> Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44148 Mon 10 Oct 2022 09:17:25 AEDT ]]> Treatment efficacy, adherence, and quality of life among women younger than 35 years in the International Breast Cancer Study Group TEXT and SOFT adjuvant endocrine therapy trials https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29891 Fri 01 Apr 2022 09:22:24 AEDT ]]>